Turan G, Olgun C, Ayten H, Toker P, Ashyralyyev A, Savas B
Protein Sci. 2023; 33(2):e4859.
PMID: 38145972
PMC: 10804680.
DOI: 10.1002/pro.4859.
Pancholi S, Simigdala N, Ribas R, Schuster E, Leal M, Nikitorowicz-Buniak J
NPJ Breast Cancer. 2022; 8(1):125.
PMID: 36446866
PMC: 9709100.
DOI: 10.1038/s41523-022-00483-1.
Downton T, Zhou F, Segara D, Jeselsohn R, Lim E
Drug Des Devel Ther. 2022; 16:2933-2948.
PMID: 36081610
PMC: 9447452.
DOI: 10.2147/DDDT.S380925.
Lee Y, Joo H, Lee E, Kim S, Jin H, Choi Y
Biomedicines. 2021; 9(8).
PMID: 34440244
PMC: 8394342.
DOI: 10.3390/biomedicines9081040.
Mottamal M, Kang B, Peng X, Wang G
ACS Omega. 2021; 6(14):9334-9343.
PMID: 33869913
PMC: 8047716.
DOI: 10.1021/acsomega.0c06362.
Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents.
Wang G
Transl Cancer Res. 2020; 9(8):4464-4468.
PMID: 32968620
PMC: 7508469.
DOI: 10.21037/tcr-20-2166.
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
Iorfida M, Mazza M, Munzone E
Breast Cancer (Dove Med Press). 2020; 12:45-56.
PMID: 32256106
PMC: 7090187.
DOI: 10.2147/BCTT.S196240.
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review.
Li J, Wang Z, Shao Z
Cancer Med. 2019; 8(5):1943-1957.
PMID: 31004402
PMC: 6536994.
DOI: 10.1002/cam4.2095.
Effects of estrogens and antiestrogens on gonadal sex differentiation and embryonic development in the domestic fowl ().
Jessl L, Lenz R, Massing F, Scheider J, Oehlmann J
PeerJ. 2018; 6:e5094.
PMID: 30002959
PMC: 6034593.
DOI: 10.7717/peerj.5094.
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky A, Dickler M
Oncologist. 2018; 23(5):528-539.
PMID: 29352052
PMC: 5947450.
DOI: 10.1634/theoncologist.2017-0423.
A Review of Fulvestrant in Breast Cancer.
Nathan M, Schmid P
Oncol Ther. 2017; 5(1):17-29.
PMID: 28680952
PMC: 5488136.
DOI: 10.1007/s40487-017-0046-2.
Emerging therapies for breast cancer.
Hu X, Huang W, Fan M
J Hematol Oncol. 2017; 10(1):98.
PMID: 28454587
PMC: 5410098.
DOI: 10.1186/s13045-017-0466-3.
Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.
Kaklamani V, Gradishar W
Oncologist. 2017; 22(5):507-517.
PMID: 28314835
PMC: 5423509.
DOI: 10.1634/theoncologist.2015-0464.
Interplay of nuclear receptors (ER, PR, and GR) and their steroid hormones in MCF-7 cells.
Hegde S, Kumar M, Kavya K, Kiran Kumar K, Nagesh R, Patil R
Mol Cell Biochem. 2016; 422(1-2):109-120.
PMID: 27632388
DOI: 10.1007/s11010-016-2810-2.
Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.
Edavana V, Penney R, Yao-Borengasser A, Williams S, Rogers L, Dhakal I
Springerplus. 2013; 2:620.
PMID: 24298433
PMC: 3841332.
DOI: 10.1186/2193-1801-2-620.
Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.
Jiang X, Wang P, Smith C, Zhu B
J Med Chem. 2013; 56(7):2779-90.
PMID: 23448346
PMC: 3666588.
DOI: 10.1021/jm3013773.
Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.
Sweeney E, McDaniel R, Maximov P, Fan P, Jordan V
Horm Mol Biol Clin Investig. 2013; 9(2):143-163.
PMID: 23308083
PMC: 3539798.
DOI: 10.1515/hmbci-2011-0004.
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
Ratanaphan A
Int J Mol Sci. 2012; 13(11):14898-916.
PMID: 23203101
PMC: 3509617.
DOI: 10.3390/ijms131114898.
Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1.
Edavana V, Yu X, Dhakal I, Williams S, Ning B, Cook I
Pharmgenomics Pers Med. 2012; 4:137-145.
PMID: 22822301
PMC: 3400326.
DOI: 10.2147/PGPM.S25418.
The terminal substituents of 7α, 6-hexanyl derivatives of estradiol determine their selective estrogen receptor modulator versus agonist activities.
Hoffman K, Foster E, Smith C
Steroids. 2012; 77(5):496-503.
PMID: 22326682
PMC: 3303951.
DOI: 10.1016/j.steroids.2012.01.011.